191 related articles for article (PubMed ID: 18341853)
1. [Which patient is a candidate for treatment with efalizumab and why?].
Puig L
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():51-61. PubMed ID: 18341853
[TBL] [Abstract][Full Text] [Related]
2. [Long-term control of psoriasis is necessary].
Sánchez Carazo JL; Martínez Casimiro L; Alegre de Miguel V
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():29-36. PubMed ID: 18341851
[TBL] [Abstract][Full Text] [Related]
3. [Clinical experience with efalizumab in the Hospital of Cruces].
Martínez de Lagrán Z; González Hermosa MR; Díaz-Pérez JL
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():74-81. PubMed ID: 18341856
[TBL] [Abstract][Full Text] [Related]
4. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
5. [Strategies to improve treatment with efalizumab].
Carrascosa JM
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():37-50. PubMed ID: 18341852
[TBL] [Abstract][Full Text] [Related]
6. [Infliximab: patients selection].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():23-9. PubMed ID: 19080988
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of short- and long-term efalizumab].
Moreno Giménez JC; Galán Gutiérrez M; Jiménez Puya R
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():9-17. PubMed ID: 18341849
[TBL] [Abstract][Full Text] [Related]
8. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
9. [Is efalizumab a safe treatment for a chronic disease?].
Daudén E; Oñate MJ
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():18-28. PubMed ID: 18341850
[TBL] [Abstract][Full Text] [Related]
10. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
Puig L; Roé E; García-Navarro X; Corella F; Alomar A
Clin Exp Dermatol; 2009 Jun; 34(4):469-75. PubMed ID: 19077105
[TBL] [Abstract][Full Text] [Related]
11. [Efalizumab].
Descamps V
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
[TBL] [Abstract][Full Text] [Related]
12. [The lymphocyte: protagonism in the new era of the biological therapies].
Gutiérrez M; Ruiz Carrascosa JC
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():2-8. PubMed ID: 18341848
[TBL] [Abstract][Full Text] [Related]
13. Efalizumab: continuous therapy for chronic psoriasis.
Cather JC; Menter A
Expert Opin Biol Ther; 2005 Mar; 5(3):393-403. PubMed ID: 15833076
[TBL] [Abstract][Full Text] [Related]
14. Clinical considerations of efalizumab therapy in patients with psoriasis.
Hamilton TK
Semin Cutan Med Surg; 2005 Mar; 24(1):19-27. PubMed ID: 15900795
[TBL] [Abstract][Full Text] [Related]
15. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
[TBL] [Abstract][Full Text] [Related]
16. Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?
Shear NH
Drug Saf; 2006; 29(1):49-66. PubMed ID: 16454534
[TBL] [Abstract][Full Text] [Related]
17. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute.
Ferrándiz C; Carrascosa JM
Br J Dermatol; 2007 Apr; 156 Suppl 2():24-9. PubMed ID: 17371320
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
19. [Final recommendations to incorporate efalizumab into the clinical practice].
García-Díez A; Ferrándiz C
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():82. PubMed ID: 18341857
[No Abstract] [Full Text] [Related]
20. [My clinical experience with efalizumab in the Hospital of Conxo].
Vázquez-Veiga HA; Seoane-Pose MJ; Fernández-Blanco MT
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():62-9. PubMed ID: 18341854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
